First Time Loading...

Swedish Orphan Biovitrum AB (publ)
OTC:BIOVF

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
OTC:BIOVF
Watchlist
Price: 25.756 USD Market Closed
Updated: May 17, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Cash Flow Statement

4.7B
+6%
Operating Cash Flow
Growth Rates:
1 Year
-3%
3 Years
+0%
5 Years
+115%
7 Years
+1 000%
10 Years
+2 406%
-19.4B
+11%
Investing Cash Flow
Growth Rates:
1 Year
-324%
3 Years
-381%
5 Years
-106%
7 Years
-8 518%
10 Years
-43 378%
15B
-12%
Financing Cash Flow
Growth Rates:
1 Year
-
3 Years
-
5 Years
+152%
7 Years
-
10 Years
+56 447%

Cash Flow Statement
Swedish Orphan Biovitrum AB (publ)

Rotate your device to view
Cash Flow Statement
Currency: SEK
Mar-2014 Jun-2014 Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024
Operating Cash Flow
Net Income
(410)
(373)
(264)
(268)
136
108
60
65
291
603
716
801
702
658
864
1 149
1 462
1 881
2 181
2 418
2 806
2 620
2 539
3 304
3 958
3 817
3 641
4 217
3 579
3 575
3 808
3 295
3 050
3 013
2 978
3 321
3 972
3 930
3 483
2 954
2 611
Depreciation & Amortization
311
312
309
0
314
315
317
320
341
366
404
441
471
485
486
0
357
358
0
485
677
984
1 602
1 589
665
1 109
1 583
2 023
2 001
1 981
1 967
2 006
2 206
2 280
2 365
2 419
2 398
2 470
2 827
3 200
3 445
Change in Deffered Taxes
(45)
0
0
0
23
11
14
12
76
170
186
165
88
61
67
0
49
(29)
0
(103)
64
168
200
411
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Non-Cash Items
209
254
208
325
(3)
15
17
14
(285)
(693)
(734)
(765)
(411)
(164)
(316)
282
127
180
257
(458)
(405)
(220)
(143)
(5)
(246)
(544)
(499)
46
316
613
637
503
912
778
833
316
(84)
93
122
1 040
1 429
Cash Taxes Paid
0
0
0
14
0
0
0
21
0
0
0
0
0
0
0
28
0
0
0
507
0
0
0
520
0
0
0
918
1 552
1 714
1 863
1 124
698
717
725
673
581
573
586
641
699
Cash Interest Paid
0
0
0
60
0
0
0
56
0
0
0
0
0
0
0
14
0
0
0
18
0
0
0
114
0
0
0
0
0
0
0
324
0
0
0
0
0
0
0
949
1 275
Change in Working Capital
58
(107)
(54)
(66)
(211)
(24)
88
96
151
48
(242)
(299)
(419)
(435)
2
(98)
(252)
(257)
(457)
(250)
(939)
(638)
(716)
(1 665)
(639)
463
(63)
(1 360)
(1 157)
(1 979)
(2 346)
(334)
(753)
(1 706)
(1 288)
(1 480)
(1 371)
(1 564)
(1 225)
(2 724)
(2 742)
Cash from Operating Activities
189
N/A
86
-54%
236
+173%
234
-1%
268
+15%
426
+59%
496
+17%
507
+2%
573
+13%
493
-14%
329
-33%
343
+4%
431
+26%
605
+40%
1 103
+82%
1 333
+21%
1 287
-3%
1 677
+30%
1 810
+8%
2 090
+15%
2 201
+5%
2 912
+32%
3 195
+10%
3 634
+14%
5 132
+41%
5 799
+13%
5 185
-11%
4 926
-5%
4 739
-4%
4 190
-12%
4 066
-3%
5 470
+35%
5 415
-1%
4 365
-19%
4 888
+12%
4 576
-6%
4 915
+7%
4 929
+0%
5 207
+6%
4 470
-14%
4 743
+6%
Investing Cash Flow
Capital Expenditures
(45)
(51)
(103)
(183)
(194)
(190)
(218)
(146)
(142)
(185)
(122)
(165)
(228)
(189)
(166)
(139)
(79)
(88)
(592)
(578)
(9 434)
(9 466)
(9 004)
(9 746)
(897)
(965)
(2 084)
(3 852)
(3 920)
(3 812)
(2 661)
(370)
(436)
(954)
(1 659)
(1 477)
(4 578)
(4 857)
(4 548)
(4 943)
(2 430)
Other Items
0
0
0
(0)
(0)
(0)
(1)
3
7
7
9
7
3
3
3
0
1
5
4
3
3
25
(3 972)
(11 939)
(11 940)
(11 966)
(8 089)
(112)
(111)
(110)
11
3
3
1
0
0
0
(16 962)
(16 961)
(16 961)
(16 961)
Cash from Investing Activities
(45)
N/A
(50)
-13%
(103)
-104%
(184)
-79%
(195)
-6%
(190)
+2%
(218)
-15%
(143)
+34%
(135)
+6%
(178)
-32%
(113)
+36%
(158)
-39%
(225)
-42%
(186)
+17%
(163)
+12%
(139)
+15%
(79)
+43%
(84)
-6%
(589)
-601%
(575)
+2%
(9 431)
-1 539%
(9 441)
0%
(12 976)
-37%
(21 685)
-67%
(12 837)
+41%
(12 931)
-1%
(10 173)
+21%
(3 964)
+61%
(4 031)
-2%
(3 922)
+3%
(2 650)
+32%
(367)
+86%
(433)
-18%
(953)
-120%
(1 659)
-74%
(1 477)
+11%
(4 578)
-210%
(21 819)
-377%
(21 509)
+1%
(21 904)
-2%
(19 391)
+11%
Financing Cash Flow
Net Issuance of Common Stock
7
7
7
7
10
22
22
22
12
24
24
24
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
89
197
205
6 168
6 129
6 076
Net Issuance of Debt
0
20
20
20
20
0
0
0
(20)
(332)
(331)
(331)
(311)
1
0
(500)
(501)
(500)
(501)
(2)
5 942
5 419
8 351
15 781
7 950
6 064
3 934
(1 570)
(875)
(214)
(1 273)
(4 123)
(4 275)
(2 786)
(2 398)
(2 553)
(1 158)
17 120
10 170
11 086
9 235
Other
0
0
0
0
0
0
0
0
0
0
(1)
(1)
0
0
0
0
0
0
0
0
0
0
0
(1)
114
82
146
288
(18)
(18)
(88)
(351)
(306)
(566)
(864)
(438)
(288)
(42)
345
(203)
(326)
Cash from Financing Activities
27
N/A
27
+1%
27
N/A
20
-25%
30
+50%
22
-27%
22
N/A
22
+1%
(8)
N/A
(308)
-3 846%
(308)
N/A
(308)
0%
(288)
+6%
0
N/A
0
N/A
(500)
N/A
(501)
0%
(500)
+0%
(501)
0%
(2)
+100%
5 942
N/A
5 419
-9%
8 351
+54%
15 780
+89%
8 064
-49%
6 146
-24%
4 080
-34%
(1 282)
N/A
(893)
+30%
(232)
+74%
(1 361)
-487%
(4 474)
-229%
(4 581)
-2%
(3 352)
+27%
(3 262)
+3%
(2 902)
+11%
(1 249)
+57%
17 283
N/A
16 683
-3%
17 012
+2%
14 985
-12%
Change in Cash
Effect of Foreign Exchange Rates
2
3
2
4
4
3
3
(2)
(3)
(1)
1
5
5
1
(5)
(1)
11
24
12
7
1
(8)
17
9
19
10
(6)
(13)
(23)
(17)
(7)
12
29
67
111
119
47
38
8
(35)
(9)
Net Change in Cash
173
N/A
65
-62%
162
+149%
74
-54%
107
+45%
260
+143%
303
+17%
385
+27%
428
+11%
7
-98%
(92)
N/A
(118)
-29%
(77)
+35%
420
N/A
935
+123%
693
-26%
718
+4%
1 117
+56%
732
-34%
1 520
+108%
(1 287)
N/A
(1 118)
+13%
(1 413)
-26%
(2 262)
-60%
378
N/A
(976)
N/A
(914)
+6%
(333)
+64%
(208)
+38%
19
N/A
48
+153%
641
+1 235%
430
-33%
127
-70%
78
-39%
316
+305%
(865)
N/A
431
N/A
389
-10%
(457)
N/A
328
N/A
Free Cash Flow
Free Cash Flow
145
N/A
36
-75%
133
+271%
51
-62%
74
+46%
235
+219%
278
+18%
361
+30%
431
+19%
308
-29%
207
-33%
178
-14%
203
+14%
416
+105%
937
+125%
1 193
+27%
1 208
+1%
1 589
+32%
1 218
-23%
1 512
+24%
(7 233)
N/A
(6 554)
+9%
(5 809)
+11%
(6 112)
-5%
4 235
N/A
4 834
+14%
3 101
-36%
1 074
-65%
819
-24%
378
-54%
1 405
+272%
5 100
+263%
4 979
-2%
3 411
-31%
3 229
-5%
3 099
-4%
337
-89%
72
-79%
659
+815%
(473)
N/A
2 313
N/A

See Also

Summary
BIOVF intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIOVF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIOVF stock valuation using valuation multiples.
Wall Street Estimates
BIOVF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIOVF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.